The atopic dermatitis space gained another player in Triveni Bio Inc., which pulled down a $92 million series A financing co-led by Atlas Venture and Cormorant Asset Management to pay for a proof-of-concept study with lead program, TRIV-509, and boost the Waltham, Mass.-based firm’s broader pipeline.